Want to see AU:PER full AI Analyst Report?
Percheron Therapeutics (PER) AI Stock Analysis
Percheron Therapeutics
(ASX:PER)
Percheron Therapeutics receives a low overall score, primarily reflecting the high risks associated with its pre-revenue status, negative earnings, and speculative technical profile. Although management has notably reduced cash burn and maintained a clean, debt-free balance sheet, the continuous erosion of the company's equity base presents significant long-term risks, potentially necessitating future dilutive capital raises to sustain ongoing research and development.
Percheron Therapeutics (PER) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 4.76M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- -0.07
- Revenue Growth
- ―
- EPS Growth
- 72.60%
- Country
- Australia
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Percheron Therapeutics Business Overview & Revenue Model
Company Description
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limite...
How the Company Makes Money
null
Percheron Therapeutics Financial Statement Overview
Summary
Percheron Therapeutics operates as a pre-revenue clinical-stage biotech. While net losses and cash burn improved significantly in 2026, and the balance sheet remains virtually debt-free, sustained operational losses continue to erode the equity base, pointing to a finite cash runway.
Income Statement
30NegativeBalance Sheet
65PositiveCash Flow
35Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -219.56K | -219.56K | -67.98K | -79.42K | -95.20K | -89.22K |
| EBITDA | -5.40M | -5.40M | -16.27M | -11.84M | -13.25M | -7.52M |
| Net Income | -4.79M | -4.79M | -14.92M | -11.92M | -11.38M | -5.81M |
Balance Sheet | ||||||
| Total Assets | 8.22M | 8.22M | 12.44M | 14.53M | 12.84M | 22.44M |
| Cash, Cash Equivalents and Short-Term Investments | 4.05M | 4.05M | 10.17M | 11.87M | 10.97M | 19.23M |
| Total Debt | 27.79K | 27.79K | 25.86K | 39.87K | 142.10K | 227.40K |
| Total Liabilities | 692.18K | 692.18K | 2.43M | 5.17M | 2.87M | 1.30M |
| Stockholders Equity | 7.53M | 7.53M | 10.00M | 9.36M | 9.98M | 21.14M |
Cash Flow | ||||||
| Free Cash Flow | -4.97M | -4.97M | -15.65M | -10.12M | -8.18M | -7.81M |
| Operating Cash Flow | -4.96M | -4.96M | -15.64M | -10.12M | -8.15M | -7.81M |
| Investing Cash Flow | -3.09M | -3.09M | -7,240 | -3,606 | -29.29K | -3,913 |
| Financing Cash Flow | 1.93M | 1.93M | 13.95M | 11.02M | -85.30K | 21.02M |
Percheron Therapeutics Peers Comparison
Overall Rating
AU:CAN53Neutral
AU:LGP45Neutral
AU:VIT44Neutral- AU:PER43Neutral
AU:IDT41Neutral
AU:PKP39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CAN | 53Neutral | AUD 8.30M | 0.30 | 64.70% | ― | -24.22% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:LGP | 45Neutral | AUD 49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% |
| AU:VIT | 44Neutral | AUD 13.25M | -2.98 | -9.80% | ― | 5.74% | -222.22% |
| AU:PER | 43Neutral | AUD 5.95M | -0.73 | -65.33% | ― | ― | 72.60% |
| AU:IDT | 41Neutral | AUD 18.20M | -6.88 | -13.81% | ― | 5.93% | 66.32% |
| AU:PKP | 39Underperform | AUD 21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:PER | Percheron Therapeutics Limited | ― | ― | ― | |
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:LGP | Little Green Pharma Ltd. | 0.06 | -0.07 | -53.85% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.02 | -0.01 | -23.81% | |
| AU:IDT | IDT Australia Limited | 0.04 | -0.02 | -26.67% | |
| AU:VIT | Cronos Australia Ltd. | 0.02 | -0.04 | -67.74% |
Percheron Therapeutics Corporate Events
Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing
Percheron Therapeutics has disclosed that its electronic FY2026 annual report released to the ASX on 19 August 2026 inadvertently omitted the final page of the Independent Auditor’s Report due to an error in the external design and production p...
Percheron Therapeutics Files ASX Corporate Governance Statement and Appendix 4G
Percheron Therapeutics Limited, an ASX-listed biotechnology company, has published its corporate governance statement for the year ended 30 June 2026 on its website, detailing how it complies with ASX Corporate Governance Council principles. The stat...
Percheron Therapeutics Adds New Shares to ASX Quotation
Percheron Therapeutics Limited has applied for quotation of 2,850 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of August 14, 2026. The small equity issuance arises from the exercise or conversion of existin...
Percheron Therapeutics names Michael Baker CEO as James Garner moves to non-executive role
Percheron Therapeutics has announced a leadership transition, with current Chief Executive Officer and Managing Director James Garner set to step down on 31 August 2026 to pursue an overseas opportunity, while remaining on the board as a non-executiv...
Percheron Advances Lead Cancer Drug Minperstobart and Raises $2.2m for New Trial
Percheron Therapeutics reported continued progress in the June quarter as it advances its lead oncology candidate HMBD-002 toward mid-stage trials. The World Health Organization has granted the drug the provisional international non-proprietary name...
Percheron Completes Manufacture of HMBD-002 Drug Substance for 2026 Trial
Percheron Therapeutics has completed manufacturing of a new batch of HMBD-002 drug substance, produced under a license agreement by Hummingbird Bioscience, with testing confirming that quality attributes meet expected standards. Final release and con...
Percheron Therapeutics Issues New Tranche of Unquoted Equity Securities
Percheron Therapeutics has issued 13.75 million unquoted options under the ASX code PERAQ, exercisable at A$0.01 and expiring on April 15, 2028, alongside a further 13.75 million unquoted securities in a new class to be confirmed. The move, executed...
Percheron Therapeutics Plans Issue of 13.75 Million Options to Bolster Capital
Percheron Therapeutics has notified the ASX of its intention to issue up to 13,750,000 options, each exercisable at $0.01 and expiring on April 15, 2028. The options are proposed to be issued on June 1, 2026, as part of a placement or other type of s...
WHO assigns proposed nonproprietary name to Percheron’s cancer drug HMBD-002
Percheron Therapeutics announced that the World Health Organization has selected “minperstobart” as the proposed international nonproprietary name for its investigational VISTA-targeting cancer therapy HMBD-002. The company expects the na...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026